Published monthly euroPLX 60 Barcelona (Spain) March 7 + 8, 2016 | Barcelona Sea Front Promenade by RauCon, Langer Anger 75, 69115 Heidelberg, Germany

Business Developer Vol. 11 # 12 | December | 2015 Featured Vacancies in Business 2015 Ending, So What’s Next Year? Development and Licensing Some call it side effects, others call it fall-out. For business developers, they are opportunities: products, portfolios, drug candi- dates under development, and assets that need to be divested following a merger. Acadia Pharmaceuticals Inc.: Director, Business Development, 2015 has seen unprecedented billion Pfizer/Allergan merger. Whatever it is, there are side based in San Diego, CA, U.S.A. mergers and acquisitions activi- The „size imperative“, as some effects which are interesting for (http://www.acadia-pharm.com) ties in our industry. Although observers put it, seems to domi- the business developer. There Aesica Pharmaceuticals Ltd.: the number of deals was prob- nate. Growth by acquisitions, is it is no merger that does not pro- Business Development Manager ably lower than in 2014, the deal strategy or just greed? Consider duce overlapping capabilities, (2 positions), based in Home value was much higher, not least that Pfizer’s tax base may shift to combined pipeline and portfolio Office, Germany/UK (http://www. because mega-mergers are en Allergan’s home base in Ireland in redundancies, or antitrust con- aesica-pharma.co.uk) vogue, culminating in the $160 order to save taxes… cerns that stand in the way of completing a merger. Imminent Alkermes Inc.: Manager, Business Complimentary Advertisement of a euroPLX 60 Barcelona Registrant divestments are what catches the Development, based in Waltham, Are you looking for competitive generics? attention of euroPLX attendees MA, U.S.A. (http://www.alkermes. Fair-Med offers more than 200 OTC and Rx MA’s with attractive and a good merger year is always com) supply. We offer worldwide license and supply agreements. Fair-Med followed by interesting offers at also facilitates the technical transfer of production to competitive Almac Group Ltd.: Business suppliers. We are present in most therapeutical areas. Some of our euroPLX Conferences. 40 key products are: Amlodipine, Carbidopa/Levodopa, Ibuprofen, Development Manager, based Imatinib, Telmisartan, Temozolomide, Raloxifene and Venlafaxine, The volumes to be divested are in Souderton, PA, U.S.A. (http:// Zoledronic. Please contact [email protected]) …or discuss considerable. Teva, for example, this opportunity with us at euroPLX 60 Barcelona! www.almacgroup.com) is expected to unload about $1 billion worth of assets to address Amdipharm Mercury Company Complimentary Advertisement of a euroPLX 60 Barcelona Registrant Limited: Business Development antitrust concerns over its deal to Analyst - BDA, based in unspeci- buy Allergan Plc’s generic drugs business, reported Reuters a few fied location, India (http://www. Calox is Looking for New Business to LA days ago, referring to „people amcolimited.com) Calox de Costa Rica offers a widely and strong distributor network in 8 countries, medical reps and more than 80 years of experience in Latin familiar with the matter“. The Antares Pharma, Inc.: Manager of America Market and we are interested for innovative products, early assets to be divested span the and advanced stage development projects (phase 2, 3 and launching), Business Development/Alliances, co-marketing, representation, joint ventures or products with United States, Europe and the based in Ewing, NJ, U.S.A. (http:// differential factors to be in license in our territories. Please contact Middle East and some of them www.antarespharma.com) [email protected] …or discuss this opportunity with us at euroPLX may show up as offers at euroPLX. 60 Barcelona! Arecor Limited: Business These days, euroPLX is finalis- Complimentary Advertisement of a euroPLX 60 Barcelona Registrant Development Associate, based ing a re-launch of its web-site in Cambridge, UK (http://www. Inhalation DPI + MDI Products For License and online partnering tools, with arecor.com) Harvest Moon Pharmaceuticals, USA is developing the folowing easier handling, streamlined generic inhalation products: fluticasone + salmeterol DPI and MDI; processes, improvements and Aspira Scientific Inc: Business formoterol + budesonide DPI and MDI; and tiotropium DPI and MDI. All are available for license in Europe and the USA. Limited territorial innovative features. And it will be Development Manager, based in licenses are available. For a commercial quote, please send a country designed for use on smart phones Milpitas, CA, U.S.A. (http://aspi- (countries) forecast (s) and target supply price(s) FOB to: rich.dicicco@ and tablets, too. The best platform rasci.com) harvestmoonpharma.com …or discuss this opportunity with us at euroPLX 60 Barcelona! to divest assets in 2016. Becton Dickinson & Co.: Sr. Almirall, S.A. acquired 100% of Complimentary Advertisement of a euroPLX 60 Barcelona Registrant Manager, Strategy & Business the Poli Group Holding S.r.l. with Development, based in San its three operative units Taurus New robotic plant for oncology products! Diego, CA, U.S.A. (http://www. Pharma GmbH, Polichem S.A. and AqVida is a German pharmaceutical company that is specialized bd.com) in the development, registration and manufacturing of oncology Polichem S.r.l. 30 Nov 2015 (www. FDFs. AqVida is finalizing construction of its new high-tech facility almirall.es) Biovest International, Inc.: to manufacture oncology products and ADCs. The facility is a major innovation for the pharmaceutical industry, using innovative robotic Business Development Director, * Co-marketing: APR Applied controlled filling processes for parenteral cytotoxics. Please contact Europe, based in unspecified [email protected] …or discuss this opportunity with us at euroPLX Pharma Research S.A. and Eris location, anywhere in Europe 60 Barcelona! Pharmaceuticals (Australia) Pty (http://www.biovest.com) Ltd. signed an agreement for the Complimentary Advertisement of a euroPLX 60 Barcelona Registrant promotion, distribution and mar- Boehringer Ingelheim: Senior keting of the Halykoo baby health- Strategic Portfolio Manager, Efarmes | Generics Out-license care product line in Australia and based in Shanghai, China, Efarmes develops in-house and looks for companies interested in licensing + supply agreements. Olmesartan +Amlodipinie +HCTZ is New Zealand. 2 Dec 2015 (www. People’s Rep. (http://www. going to be our next development for the treatment of Hypertension. apr.ch) boehringer-ingelheim.com) We are going to start the BE studies next January 2016 and the registration dossier will be ready sometime in May-June 2016. Should * Acquisition: Aqua Pharma­ Bristol-Myers Squibb Company: you be interested in this triple combination, please feel free to contact us at [email protected] …or discuss this opportunity with us at ceuticals, LLC acquired the Executive Director, Business euroPLX 60 Barcelona! U.S. rights to two dermatology Development, based in New products, VELTIN® (clindamycin Brunswick, NJ, U.S.A. (http://www. Complimentary Advertisement of a euroPLX 60 Barcelona Registrant phosphate and tretinoin) Gel, bms.com) We Are Developing - We Are Manufacturing 1.2%/0.025% and ALTABAX® Chiesi Farmaceutici SpA: Business FERRAZ LYNCE offers a strategic partnership under in-licensing and (retapamulin) Ointment, 1%, by out-licensing opportunities. For competitive markets, differentiated Development & Licensing the global pharmaceutical com- solutions! Our team has added new products with full scientific and Manager, based in Parma, Italy technological support regarding the Respiratory, Circulatory and pany Almirall, parent company (http://www.chiesigroup.com) CNS areas. We also provide the unique quality and lead time of our of Aqua, from GlaxoSmithKline. Manufacturing, Packaging and Quality Control services at IBERFAR. Both VELTIN® and ALTABAX® will Please contact [email protected] …or discuss this opportunity Collegium Pharmaceutical, Inc.: with us at euroPLX 60 Barcelona! be promoted through Aqua in the Manager, Business Development, United States. 1 Dec 2015 (www. Sistenic, following an 18 year based in Canton, MA, U.S.A. aquapharm.com) (http://www.collegiumpharma. Recent BD&L Manage­ career in hedge funds man- com) ment Changes agement and most recently in * Acquisition: Astellas Pharma investment banking, has been Inc. and Ocata Therapeutics, Inc. CoNCERT Pharmaceuticals * Affimed Therapeutics AG: appointed as Head of Corporate have entered into a definitive Inc.: Senior Director, Business Andrew Curtis, who spent more Development (Press Release 3 Dec agreement under which Astellas Development, based in than twenty years in the phar- 2015) will acquire Ocata through Laurel Lexington, MA, U.S.A. (http:// maceutical and biotechnology Acquisition Inc., a wholly-owned www.concertpharma.com) sectors, focusing on the licens- subsidiary of Astellas US Holding. ing, commercial development Company News 10 Nov 2015 (www.astellas.com) Crown Bioscience: Director and commercialization of new Business Development & *Co-Marketing: Aeterna Zentaris medicines for rare and neglected * Divestment: AstraZeneca has Marketing Japan, based in Tokyo, Inc. finalised a co-marketing diseases, has been appointed as entered into an agreement Japan (http://www.crownbio. agreement with Armune Head of Corporate Strategy and with Perrigo Company plc for com) BioScience, Inc. that will allow the Business Development. (Press the divestment of US rights to Company to promote Armune’s Release 2 Dec 2015) Entocort® (budesonide), a gastro- Dr. Willmar Schwabe Arzneimittel: APIFINY®, the only cancer specific, enterology medicine for patients Business Development & non-PSA blood test for the detec- * Catalent Pharma Solutions, Inc.: with mild to moderate Crohn’s Licensing Manager (descr. in tion of prostate cancer. 1 Dec 2015 Kevin Hambly, after spending nine disease, an area of medicine out- German), based in Karlsruhe, (www.aezsinc.com) years at Seattle Genetics, where he side AstraZeneca’s strategic focus. Germany (http://www.schwabe. most recently served as Director Under the terms of the agree- de) * Investment: Almac Group has of Business Development and was confirmed a £16 million invest- ment, Perrigo will pay AstraZeneca responsible for leading out-licens- Duchesnay Inc.: Senior Manager, ment to expand its formulation $380 million. 23 Nov 2015 (www. ing activities, has been appointed Business Development, based and analytical development astrazeneca.com) to the position of Vice President, in Blainville QC, Canada (http:// services to meet ongoing client Business Development and * Investment: BioGaia reporst www.duchesnay.com) demand. 9 Nov 2015 (www.almac- Licensing for Catalent Biologics. that the company made a second group.com) F. Hoffmann - La Roche Ltd.: (Press Release 9 Dec 2015) investment of SEK 4 million in Director Business Development, * Acquisition: Laboratorios Gothenburg based MetaboGen * Nohla Therapeutics Inc.: Michael and now owns 27% of its share based in Pleasanton, CA, U.S.A. capital. 1 Dec 2015 (www.biogaia. discovery, development and and Florence, United States. In an (http://www.roche.com) com) commercialisation of innovative effort to minimise job reductions, treatments and therapies for rare the company is actively looking F. Hoffmann - La Roche Ltd.: * Acquisition: Bristol-Myers and orphan diseases, appointed into divestment opportunities for Global BD and M&A Manager, Squibb Company has com- Durbin, a specialist provider of these facilities. 12 Nov 2015 (www. Roche Diagnostics, based in pleted the previously announced Managed Access Programs, to roche.com) Basle, Switzerland (http://www. planned acquisition of Cardioxyl manage the warehousing and roche.com) Pharmaceuticals, Inc. The trans- * Licensing: Grünenthal supply chain for its products. action includes full rights to announced an exclusive license Fresenius AG: Director New Initially this agreement will cover Cardioxyl’s lead asset CXL-1427, a agreement with Depomed, Inc. on Therapeutic Area & Business Emmaus’ pharmaceutical grade novel nitroxyl (HNO) donor (prod- the development and commer- Development Mature & Emerging L-glutamine treatment (PGLG), rug) in Phase 2 clinical develop- cialisation of Cebranopadol for the Markets, based in Oberursel, which is currently under clinical ment as an intravenous treatment U.S. and Canada. Cebranopadol Germany (http://www.fresenius- development having completed for acute decompensated heart is a novel, first in class, potent ag.com) its Phase 3 trial for the manage- failure (ADHF). 8 Dec 2015 (www. analgesic for chronic pain which ment of sickle cell disease (SCD). 3 bms.com) has demonstrated its efficacy in GeneData AG: Business Dec 2015 (www.emmausmedical. Development Manager, based in multiple Phase II trials in moder- * Acquisition: BSN medical com) Basle, Switzerland (http://www. ate to severe chronic pain. The announces the acquisition of genedata.com) * Divestment: Roche plans to product is suited for oral, once- Wright Therapy Products, Inc., a restructure its manufacturing a- day treatment. Under the terms leading manufacturer of compres- Genentech, Inc.: Manager/ network for small molecules to of the agreement, Depomed, Inc. sion therapy systems, to become a Senior Manager- Research address current underutilisation will take responsibility for further full solution provider of lymphoe- Tools Technologies, Business as a result of its evolving portfolio. development, marketing and dema care products and expand Development, based in South San A new generation of specialised sales of Cebranopadol in the U.S. its portfolio of solutions used to Francisco, CA, U.S.A. (http://www. medicines based on small mol- and Canada, while Grünenthal treat chronic venous insufficiency. gene.com) ecules requires novel manufac- will keep the rights for the rest 24 Nov 2015 (www.bsnmedical. turing technologies and will be of the world. Depomed will pay Genentech, Inc.: Associate com) produced in lower volumes than Grünenthal an upfront payment Director, Oncology Business traditional medicines. As a result, of $25 million in cash, royalties on Development, Genentech * Name change: Chugai Roche plans to exit four manufac- net sales of Cebranopadol as well Partnering, based in South San Pharmaceutical Co., Ltd. has turing sites in Clarecastle, Ireland; as sales milestones. 17 Nov 2015 Francisco, CA, U.S.A. (http://www. announced that Chugai Pharma Leganes, Spain; Segrate, Italy; (www.grunenthal.com) gene.com) Marketing Ltd., a wholly-owned subsidiary of Chugai located in Complimentary Advertisement of a euroPLX 60 Barcelona Registrant Genentech, Inc.: Associate London, changed its corporate Tecnimede Products for Out Licensing Director, Business Develoment name to Chugai Pharma Europe (Immunology and Infectious We are a privately owned group of pharmaceutical companies Ltd. effective November 27. 1 Dec dedicated to the development, registration, manufacturing, promotion Disease), based in South San 2015 (www.chugai-pharm.com) and sale of pharmaceutical products for human use. During the 1st Francisco, CA, U.S.A. (http://www. QRT 2016 Tecnimede will have the following dossiers to offer: gene.com) * IPR: Dr. Reddy’s Laboratories Ltd. Clopidogrel+ASA | Etoricoxib | Pioglitazone+Metformin has completed the purchase of Please contact [email protected] …or discuss this opportunity with Genfit Corp.: VP Business worldwide exclusive intellectual us at euroPLX 60 Barcelona! Development, based in Boston, property rights for Fondaparinux MA, U.S.A. (http://www.genfit. sodium, its generic anti-coagulant Complimentary Advertisement of a euroPLX 60 Barcelona Registrant com) drug from its Australian partner, New Patented Formula from Biolab Alchemia Limited. 18 Nov 2015 Henry Schein, Inc.: Business Biolab has developed a new patented formulation as an innovative (www.drreddys.com) synergy for mitochondrial protection. It ensures the action in various Development Specialst - Chicago, pathologies, such as: myalgia or weakness in the lower limbs produced based in Chicago, IL, U.S.A. * Acquisition: Eisai Co., Ltd.’s China by drugs, diabetes, metabolic syndrome, renal failure, among others. (http://www.henryschein.com) Please contact: [email protected] …or discuss this holding company Eisai China opportunity with us at euroPLX 60 Barcelona! Holdings Ltd. (Location: Suzhou, Heumann Pharma: Licensing Jiangsu Province) has signed an Complimentary Advertisement of a euroPLX 60 Barcelona Registrant Manager, based in Nuremberg, agreement to purchase 100% Germany (http://www.heumann. We Provide Products Ready to Market! of the shares of Liaoning TianYi de) For 20 years, Substipharm has been providing quality products Biological Pharmaceutical Co., Ltd. & services to quality partners! We invest in the development and Horizon Pharma plc: Director, 27 Nov 2015 (www.eisai.co.jp) manufacturing of our own products to offer you a wide range of pharmaceutical generic, OTC & niche products. We are by your side Business Development, based in * Distribution: Emmaus Life from the registration of the dossier to the supply of the finished Deerfield, IL, U.S.A. (http://www. product. Our team would be pleased to provide you with additional Sciences, Inc., a biopharmaceuti- horizonpharma.com/) information. Please contact us at [email protected] …or cal company engaged in the discuss this opportunity with us at euroPLX 60 Barcelona! Horizon Pharma plc: Vice * Distribution: Guerbet completed company, an exclusive license to (www.jnj.com/) President Business Development, the acquisition of Mallinckrodt’s market and sell Innovus Pharma’s * Acquisition: Lannett Company, based in Deerfield, IL, U.S.A. “Contrast Media and Delivery products: Zestra®, Zestra Glide®, Inc. has completed the acquisition (http://www.horizonpharma. Systems” business. The acquisition EjectDelay®, Sensum+® and of Kremers Urban Pharmaceuticals com/) will bring Guerbet’s employee Vesele® in Malaysia. Under the Inc. (KU), the U.S. specialty generic base to 2,500 people and is agreement, Innovus Pharma will Hovione: Business Development pharmaceuticals subsidiary of expected to nearly double our receive an upfront payment and Manager, based in Lisboa, global biopharmaceuticals com- turnover to €800M. 27 Nov 2015 is eligible to receive up to $34 Portugal (http://www.hovione. pany UCB S.A for $1.23 Billion. 27 (www.guerbet.com) million dollars in sales milestone com) Nov 2015 (www.lannett.com) payments plus an agreed-upon * Licensing: Hanmi Impax Laboratories, Inc.: transfer price. 3 Dec 2015 (www. * Acquisition: LEO Pharma A/S, Pharmaceuticals Co. Ltd. has Associate Director, Business innovuspharma.com/) and Astellas Pharma Inc. have entered into an exclusive Development, based in Hayward, entered into an Asset Purchase license, agreement with Janssen * Acquisition: Johnson & Johnson CA, U.S.A. (http://www.impaxlabs. Agreement under which Astellas Pharmaceuticals, Inc., for the completed the acquisition of com) will transfer its global dermatol- development and commerciali- Novira Therapeutics, Inc., a pri- ogy business to LEO Pharma for Ironwood Pharmaceuticals, sation of oxyntomodulin-based vately held, clinical-stage biophar- € 675 million. 11 Nov 2015 (www. Inc.: Senior Manager, Business therapies including Hanmi’s maceutical company developing leo-pharma.com) Development, Search, based in HM12525A (LAPSGLP/GCG), a innovative therapies for curative Cambridge, MA, U.S.A. (http:// novel biologic GLP-1/Glucagon treatment of chronic hepatitis B * Divestment: Meda has signed ironwoodpharma.com) dual receptor agonist to treat virus (HBV) infection. 4 Dec 2015 an agreement with The Riverside diabetes and obesity, which is Johnson & Johnson: Director expected to enter Phase 2 stud- Complimentary Advertisement of a euroPLX 60 Barcelona Registrant Business Development, based ies next year. Janssen will obtain Natrapharm: Unique Chance in the Philippines in Irvine, CA, U.S.A. (http://www. exclusive worldwide rights, except As second largest national pharma company (ethical field) in the Philippines known for its high quality products and competent jnj.com/) Korea and China, to develop and field force (500) is looking for a medical food with indications and commercialise HM12525A. Hanmi clinical trials. Natrapharm´s objective: to market pharmaceutical Johnson & Johnson: Business will receive an upfront payment of products in the Philippine territory through licensing and/or supply Development Manager - Janssen agreements with national and international companies by providing $105 million, and is eligible for up Infectious Disease, based in its partners with comprehensive, integrated service. Please contact to $810 million in potential clinical [email protected] …or discuss this opportunity with us at Springfield, IL, U.S.A. (http://www. euroPLX 60 Barcelona! development, regulatory and sales jnj.com/) milestones. Hanmi Pharmaceutical Complimentary Advertisement of a euroPLX 60 Barcelona Registrant Johnson & Johnson: Business Co., Ltd. also announced a world- Development Manager Advanced wide license agreement with Day 1 launch opportunities from Alembic Pharma Oncology, based in Moscow, Sanofi to develop a portfolio of We are one of the oldest Pharma companies from India with vertical integration into API, FDF & BE studies. We focus on development and experimental, long-acting diabe- Russian Federation (http://www. manufacturing of solid dosages for regulated markets and we are jnj.com/) tes treatments. Hanmi will receive supplying to USA, 20+ EU countries, Australia etc. We are offering an upfront payment of EUR 400 products for day-1 launch in EU and are looking for partners to Medimmune, Inc.: Associate complement our strengths with theirs to penetrate the market. Please million and is eligible for up to contact [email protected] …or discuss this opportunity with Director / Director, Partnering & EUR 3.5 billion in development, us at euroPLX 60 Barcelona! Strategy, based in Gaithersburg, registration and sales milestone, MD, U.S.A. (http://www.medim- as well as double digit royalties Complimentary Advertisement of a euroPLX 60 Barcelona Registrant mune.com) on net sales. Sanofi will obtain an Vinchem offers NSAID for dysmenorrhea MedMira Laboratories: Business exclusive worldwide license. 9 and Vinchem’s first generic product for EU markets is available for licensing to interested partners; product is Naproxen base 250mg and Development and Sales 5 Nov 2015 (www.hanmipharm. 500mg tablets (ref. Naprosyn by Roche) available in bulk, bulk blisters com) Associate, based in Atlanta, GA, of 10 or finished pack. New dossier with BE study ready for registration U.S.A. (http://www.medmira.com) in March 2016. All markets available apart from Italy, Nordic and * Divestment: Hikma MENA regions. Please contact [email protected] …or discuss this opportunity with us at euroPLX 60 Barcelona! Mega Lifesciences Ltd.: Business Pharmaceuticals PLC has agreed Development Manager (descr. in to sell the manufacturing facili- Complimentary Advertisement of a euroPLX 60 Barcelona Registrant Thai), based in Bangna, Bangkok, ties previously owned by Ben Thailand (http://www.megawe- Venue Laboratories, Inc, based LAINCO offers quality finished products care.com) in Bedford, Ohio, to Xellia Pharmaceuticals. 25 Nov 2015 LAINCO is a solid Spanish GMP Pharmaceutical and chemical company with more than 80 years of experience with high quality products. Moderna Therapeutics: (www.hikma.com) Specialized in Gastroenterology and Antisepsia, but with other Director/Sr. Director, Business range of best sellers products, LAINCO offers all its several years of experience for the companies that are looking for in-licensing Development, based in * Distribution: Innovus new products on their markets. We are open to discuss all kind of Pharmaceuticals, Inc. granted Cambridge, MA, U.S.A. (http:// model business. Please contact [email protected] …or discuss this to Bio Task SND BHD, a Malaysia opportunity with us at euroPLX 60 Barcelona! modernatx.com/) Complimentary Advertisement of a euroPLX 60 Barcelona Registrant * Acquisition: Pivot Pharma­ ceuticals Inc., an emerging bio- Multipharma SA: Business Grünenthal PRO – Your CMO+ technology company engaged in Development Manager, based We offer our excellence, innovation and service reliability for your the development of therapeutics in Berlin, Germany (http://www. success. As full service CMO we are experienced in manufacture of to meet unmet medical needs APIs, semi-solids, solid and liquid oral dosage forms, in packaging, multipharma.ch) storage and distribution of controlled substances.. Please contact in women’s health, has com- [email protected] …or discuss this opportunity with us at pleted the acquisition of IndUS NextPharma: Business euroPLX 60 Barcelona! Development Manager, based in Pharmaceuticals Inc. Financial Göttingen, Germany (http://www. Complimentary Advertisement of a euroPLX 60 Barcelona Registrant terms of the transaction were not nextpharma.com) disclosed. 23 Nov 2015 (www.piv- Mitelos offers a new concept of oral care otpharma.com/) Novartis Pharma AG: Head BD&L, Mitelos has developed, made a patent application and registered WASHDENT® , a truly ingenious and innovative new concept within oral Asia Cluster, based in Singapore, * Merger: POZEN Inc. and Tribute care. WASHDENT® is a dietary supplement that allows an “any time, any Singapore (http://www.novartis. place” dental cleaning procedure when toothbrushing is not possible. Pharmaceuticals Canada Inc. com) Please contact [email protected] …or discuss this opportunity confirmed their merger plans with us at euroPLX 60 Barcelona! and announced that they have Novartis Pharma AG: Executive entered into an amended agree- Complimentary Advertisement of a euroPLX 60 Barcelona Registrant Director, Business Development & ment and plan of merger, which Licensing, based in Princeton, NJ, Lab Vinas seeks distributors in fast growing markets among other things, moves the U.S.A. (http://www.novartis.com) Lab Vinas (LV) is a family-owned pharmaceutical company with domicile for their proposed parent international presence, which was founded in Barcelona in 1911. LV researches, develops, manufactures and markets drugs and company, Aralez Pharmaceuticals Novartis Pharma AG: Business pharmaceutical products (OTC, Medical devices, Cosmetics and Food Inc., from Ireland to Canada. 7 Dec Development & Licensing supplements) in a wide spectrum of therapeutic areas. LV offers top- 2015 (www.pozen.com) Manager, based in Freiburg, of-the-line products in dermatology, gynaecology, ophthalmology, pain and paediatrics to healthcare professionals and consumers. Please Germany (http://www.novartis. contact [email protected] …or discuss this opportunity with us at * Licensing: Quantum Pharma com) euroPLX 60 Barcelona! Plc announced three out-licens- Company for the sale of Euromed licensing and investment agree- ing deals in Germany, though Novella Clinical: Director, Business S.A., a business-to-business manu- ments valued at up to $50 Mn Lamda (UK) Limited, Lamda Development, Oncology, based in facturer of herbal extracts and with Hefei Tianhui Incubator of Laboratories SA and Lamda Home Office, U.S.A. (http://www. natural active substances located Technologies Co., Ltd. for exclusive Pharmaceuticals SA, part of its novellaclinical.com/) in Spain. The total consideration is rights to market Oramed’s oral Niche Pharmaceutical division. Novella Clinical: Director, EUR 82 million in upfront cash for insulin capsule, ORMD-0801, in Under the three licensing, royalty Business Development- Germany/ the shares of Euromed. The unit China, Hong Kong and Macau. 30 and supply agreements, Lamda Eastern Europe, based in unspeci- generates sales of around EUR 40 Nov 2015 (www.oramed.com) will out-license two generic plus fied location, Germany (http:// million and an EBITDA margin of and one generic dossiers which * Acquisition: Perrigo Company www.novellaclinical.com/) around 20% on an annual basis. 1 Lamda developed. The total fixed plc will acquire Entocort® (bude- Dec 2015 (www.meda.se) licensing fee from these three Novozymes A/S: Project Manager, sonide) capsules as well as the agreements will be, in aggregate, Business Development, based * Licensing: Moberg Pharma AB authorised generic capsules €375,000. 30 Nov2015 (www. in Beijing, China, People’s Rep. and Meda have agreed to amend marketed by Par Pharmaceuticals quantumpharmagroup.com) (http://www.novozymes.com) their existing license and distribu- within the U.S. from AstraZeneca tion agreement so Moberg regains plc for $380 million. 23 Nov 2015 * Acquisition: Sucampo Oncodesign S.A.: Business rights to the nail product in cer- (www.perrigo.com) Pharmaceuticals, Inc., a global Development Manager, based tain EU markets. This includes UK, biopharmaceutical company, in Dijon, France (http://www. * Acquisition: Pfizer Inc’s and Poland, the Chech Republic and announced the completion of its oncodesign.com) Allergan plc’s boards of directors the Baltic countries. The two com- acquisition of R-Tech Ueno and have unanimously approved, and Pacira Pharmaceuticals, Inc.: panies maintain their partnership all remaining outstanding shares. the companies have entered into, Executive Director, Business in the remaining thirteen markets Sucampo acquired R-Tech Ueno a definitive merger agreement Development, based in where the product has been for 32.8 billion Japanese Yen (JPY), under which Pfizer will combine Parsippany, NJ, U.S.A. (http:// launched under the brand names or approximately $275 million. 7 with Allergan in a stock transac- pacira.com) Naloc and Nalox. 10 Nov 2015 Dec 2015 (www.sucampo.com) tion currently valued at $363.63 (www.mobergderma.se) Panacea Biotec Ltd.: Sr. Manager/ per Allergan share, for a total * Acquisition: Tarrex Biopharma AGM – Business Development – * Licensing: Oramed Pharma­ enterprise value of approximately Ltd has acquired a 33% stake in Contract Research (CRO), based ceuticals Inc., a clinical-stage $160 billion, based on the closing Aranda Pharma Ltd of Finland. The in New Delhi, India (http://www. pharmaceutical company focused price of Pfizer common stock of two small biopharma companies panaceabiotec.com) on the development of oral drug $32.18 on November 20, 2015. 23 will be co-developing Aranda’s delivery systems, announced Nov 2015 (www.pfizer.com) androgen receptor antagonist Piramal Healthcare: Chief today it has signed definitive for the treatment of Castration Manager – Business Resistant Prostate Cancer. 3 Nov ics, supplements, and medical Development, based in Mumbai, 2015 (www.tarrexbio.com) devices. India (http://www.piramal.com) * Investment: Torrent Pharma­ Chemineau Labs (www.chem- PPD, Inc.: Executive Director, ceuticals Ltd has commenced ineau.com) is a CDMO which Business Development commercial operations at its is located in Vouvray, France, (Strategic Partnerships), based new plant in Dahej. This is the specialised in liquid and pasty in Morrisville, NC, U.S.A. (http:// Company’s 5th formulation Plant forms manufacturing and filling: www.ppdi.com) and the 2nd API Plant. The facility contract development, scale-up is being set up in a two phases. transfer, purchasing, production, Purdue Pharma L.P.: Senior The total investment made in the regulatory affairs, etc. Manager - Business Development first phase of the plant is over Rs. Liaison, based in Stamford, CT,, Based in Milan, Italy, Guna Spa 650 crores (6.5 bn). 5 Nov 2015 U.S.A. (http://www.pharma.com) (www.gunainternational.com) (www.torrentpharma.com) produces and distributes low Remedica Ltd: Business * Divestiture: UCB completed its dose medicines, medical devices, Development Officer, based in previously announced transaction food supplements and cosmetics. Limassol, Cyprus (http://www. providing for the sale of UCB’s Guna’s products are distributed in remedica.eu) U.S. specialty generics subsidiary, over 40 countries.

Rigel Pharmaceuticals Inc.: Dir., Kremers Urban Pharmaceuticals Laboratorios Vinas (www.vinas.es) Business Development/Market Inc., to Lannett Company, Inc. is a family-owned pharmaceutical Strategy, based in South San Kremers has been sold by UCB to company with international pres- Francisco, CA, U.S.A. (http://www. Lannett for total consideration of ence. The company is based in rigel.com) approximately US$ 1.23 billion, Barcelona, Spain, and researches, consisting of cash consideration of develops, manufactures and mar- Sanofi US: Area Business US$ 1.03 billion (subject to certain kets drugs and pharmaceutical Development Manager, based in adjustments) and US$ 200 million products (OTC, medical devices, South-West, UK, UK (http://www. senior unsecured notes issued cosmetics, food supplements) in sanofi.us) to UCB by Lannett. 25 Nov 2015 a wide spectrum of therapeutic (www.ucb.com) Takeda Pharmaceuticals areas with an emphasis on der- North America, Inc.: Business * Acquisition: Xellia Pharma­ matology, dermo-cosmetics and Development Manager - Mexico, ceuticals has acquired manufac- gynaecology. based in Mexico, Mexico (http:// turing facilities in Bedford, Ohio, Working from our state-of-the- www.takeda.us/) from a wholly owned subsidiary art facilities across the United of Hikma Pharmaceuticals. 25 Nov Takeda Pharmaceuticals North States and Europe, Sharp Clinical 2015 (www.xellia.com) America, Inc.: Director, PV Services (www.sharpservices.com) Business Development & Alliance provide unique and often com- Management, based in Boston, euroPLX Newcomers at plex commercial and clinical pack- MA, U.S.A. (http://www.takeda. euroPLX 60 Barcelona aging solutions to the pharmaceu- us/) Here is part 1 of companies tical and biotechnology industry: cost-effective blister packaging, VirtualScopics, Inc.: Director of which registered for euroPLX 60 bottling, pouches and stick packs, Business Development, based in Barcelona (March 7 + 8, 2016) and compliance packaging, formula- Rochester, NY, U.S.A. (http://www. are newcomers to euroPLX, i.e. tion and manufacturing services, virtualscopics.com) they have never had a delegate at a euroPLX Conference before: label design and printing. WuXi PharmaTech Co Ltd: Director of Business Development Headquartered in Tokyo, CBC for Analytical Development & Corporation Limited (www.glob- Formulation Development, based al-cbc.com) is a manufacturer, a in unspecified location, U.S.A. trading company, and a full range (http://www.wuxiapptec.com) supplier of chemicals, synthetic resins, and pharmaceuticals to electronics components & devices, security devices, and more. For More BD&L vacancies in pharma the pharmaceutical industry, CBC and biotech are regularly listed offers API/Intermediates, excipi- on www.raucon.com ents, peptide nucleic acid, cosmet- Responsible Editor: Dr. Norbert Rau